Medplum vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 38)
Medplum logo

Medplum

EmergingHealthcare

General

"Firebase for healthcare" open-source FHIR EHR API infrastructure; YC S22 $550K with $1.2M revenue serving thousands of health tech developers competing with Google Cloud Healthcare API for HIPAA-compliant infrastructure.

AI VisibilityBeta
Overall Score
D38
Category Rank
#463 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
32
Gemini
36

About

Medplum is a San Francisco-based open-source EHR and healthcare API infrastructure company — often described as "Firebase for healthcare" — providing FHIR-compliant API infrastructure, clinical data management, and workflow tools that healthcare developers use to build EMR-adjacent applications, care management platforms, and health tech products without building from scratch the compliance, data modeling, and interoperability layers that healthcare applications require. Founded in 2021 and backed by Y Combinator (S22) with $550,000 raised, Medplum achieved $1.2 million in revenue in 2024 serving thousands of developers globally building on the open-source platform.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

38
Overall Score
90
#463
Category Rank
#2
81
AI Consensus
83
stable
Trend
stable
39
ChatGPT
92
32
Perplexity
93
36
Gemini
89
40
Claude
96
38
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.